Choosing Initial Antiretroviral Therapy: Current Recommendations for Initial Therapy and Newer or Investigational Agents.

摘要: There is general consistency among US and European guidelines regarding the initiation of antiretroviral therapy for HIV-infected individuals. Recent ongoing trials comparing regimens may lead to reevaluation initial treatment choices. The choice regimen will also likely be affected by development, evaluation, availability newer drugs. This article reviews currently recommended characteristics selected current investigational drugs, including nucleotide analogue reverse transcriptase inhibitor tenofovir alafenamide, nonnucleoside doravirine, integrase strand transfer cabotegravir, HIV entry BMS-663068, maturation BMS-955176. summarizes a presentation Roy M. Gulick, MD, MPH, at IAS-USA continuing education program, Improving Management Disease, held in New York, March 2015 September 2015.